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Abstract
Background: Vaginal progesterone and 17α- hydroxyprogesterone (17α- OHP) are 
both used to prevent preterm delivery in women who have experienced spontaneous 
preterm delivery (SPTD) previously. Randomized trial data of the comparative effec-
tiveness of these interventions have been mixed.
Objectives: To compare the efficacy of intramuscular 17α- OHP and vaginal progester-
one in the prevention of recurrent SPTD.
Search strategy: Cochrane Central Register of Controlled Trials, African Journals 
Online, Embase, Google Scholar, ISI Web of Science, LILACS, CINAHL, PubMed, and 
registers of ongoing trials were searched using keywords related to 17α- OHP, vaginal 
progesterone, and preterm delivery.
Selection criteria: Randomized controlled trials published between January 1, 1966, 
and November 30, 2016, comparing 17α- OHP and vaginal progesterone for the pre-
vention of recurrent SPTD during singleton pregnancies were included.
Data collection and analysis: Study data were extracted and meta- analyses were per-
formed when outcomes were comparable.
Main results: The meta- analyses included data from three randomized trials. Lower 
rates of SPTD before 34 weeks (relative risk 0.71, 95% confidence interval 0.53–0.95) 
and before 32 weeks (relative risk 0.62, 95% confidence interval 0.40–0.94) of preg-
nancy were observed among patients treated with vaginal progesterone.
Conclusions: Vaginal progesterone and 17α- OHP were comparable for the prevention 
of recurrent SPTD in singleton pregnancies; vaginal progesterone could be superior.
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1  | INTRODUCTION
Preterm delivery has become a major public health problem owing to 
its contribution to maternal adverse events as well as neonatal mor-
bidity and mortality; despite its decreasing incidence in the USA, it 
is a leading cause of long- term disability.1 In the Centers for Disease 
Control and Prevention National Center for Health Statistics delivery 
data for 2013,2 the preterm delivery rate had decreased to 11.39% of 
all live deliveries. The use of progesterone therapy—vaginal progester-
one and intramuscular 17α- hydroxyprogesterone acetate—has been 
demonstrated to be a major contributor to the decreasing incidence 
of preterm delivery.3
Based on randomized clinical trial data,4 intramuscular 17α- 
hydroxyprogesterone (17α- OHP) has been approved by the US Food 
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and Drug Administration for the prevention of recurrent preterm 
delivery in patients who have experienced preterm delivery previ-
ously. Data from 459 women with singleton pregnancies and a his-
tory of spontaneous preterm delivery (SPTD) at 20–36+6 weeks of 
a singleton pregnancy were included and the efficacy of 17α- OHP 
was compared with placebo. Weekly 250- mg doses of intramuscular 
17α- OHP, started at 16–20+6 weeks of pregnancy, were associated 
with a reduced incidence of SPTD prior to 35 weeks, 37 weeks, and 
32 weeks of pregnancy.4 In comparison with placebo, 17α- OHP was 
also associated with significant decreases in neonatal oxygen supple-
mentation and intraventricular hemorrhage.4 Based primarily on these 
data,4 17α- OHP has been recommended for all women with a history 
of SPTD at 20–36+6 weeks of pregnancy.5
By contrast, vaginal progesterone has only been recommended for 
use in the prevention of SPTD in patients with no history of SPDT and 
with a short cervix identified incidentally during the second trimester 
of pregnancy. However, the multicenter randomized controlled trial 
conducted by Fonseca et al.6 demonstrated that vaginal progesterone 
was effective in patients without shortened cervical length. This study 
reported that nightly 200- mg doses of vaginal progesterone, started 
at 24 weeks of pregnancy and continuing until 34 weeks, was asso-
ciated with a significant decrease in SPTD before 34 weeks of preg-
nancy irrespective of cervical length.6 Notably, no increased benefit 
was recorded among patients with a history of at least one SPTD.
Current guidelines for patients with a history of SPTD and 
no evidence of a shortened cervix vary. The American College of 
Obstetricians and Gynecologists recommends progesterone adminis-
tration for the prevention of subsequent SPTDs but does not recom-
mend a specific progesterone formulation.5 The US Food and Drug 
Administration has approved only intramuscular progesterone for the 
treatment of these patients; this stance is based largely on the study of 
Meis et al.4 from 2003. There have only been several studies that have 
made head- to- head comparisons of intramuscular and vaginal proges-
terone to prevent recurrent preterm delivery in patients with normal 
or unknown cervical length.7–9 Further, to the best of our knowledge 
no known systematic reviews or meta- analyses have compared the 
efficacy of intramuscular 17α- OHP and vaginal progesterone, despite 
randomized trial data being available. Therefore, the aim of the present 
study was to compare the efficacy of 17α- OHP and vaginal proges-
terone in preventing SPTD in patients who have experienced SPTD 
previously.
2  | METHODS
The present study was performed in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta- analyses (PRISMA) 
guidelines.10
2.1. | Literature search
The African Journals Online (AJOL), Cochrane Central Register 
of Controlled Trials, Embase, Google Scholar, ISI Web of Science, 
LILACS, CINAHL, and PubMed databases, and several clinical trial 
registries (http://www.nihr.ac.uk; www.clinicaltrials.gov; www.umin.
ac.jp/ctr; www.anzctr.org.au; www.controlled-trials.com; and www.
centerwatch.com) were searched for randomized controlled trials that 
compared intramuscular 17α- OHP and a vaginal formulation of pro-
gesterone. Databases were searched from inception until November 
30, 2016. The terms “17 alpha hydroxyprogesterone caproate”, “vagi-
nal progesterone”, “prometrium”, “Makena”, “crinone”, “prochieve”, 
“endometrin”, “preterm labor”, “recurrent”, “spontaneous preterm”, 
“preterm contractions”, and “preterm birth” were used to search for 
articles. Proceedings of international society meetings where preterm 
delivery was an identified focus were also considered. If multiple ver-
sions of publications were available, the most complete, fully supple-
mented versions were reviewed where available.
2.2 | Study selection
Randomized clinical trials that included vaginal progesterone and 
intramuscular 17α- OHP as interventions for the prevention of 
recurrent preterm delivery of singleton pregnancies irrespective 
of cervical length were included. The exclusion criteria were: (1) if 
progestational agents were used for tocolysis and not specifically to 
prevent recurrent preterm delivery in asymptomatic patients; (2) if 
two form of vaginal progesterone were compared for the preven-
tion of preterm delivery; (3) if trials were quasi- randomized; and 
(4) if English translations were unavailable for foreign- language 
articles. Published abstracts without accompanying full- text manu-
scripts were excluded if there was insufficient detail to determine 
study eligibility. Authors of published manuscripts were contacted 
if additional information on study methods were needed. Qualifying 
studies were reviewed independently by two researchers (A.C.E. and 
E.O.) with subsequent discussion to reach ultimate inclusion deci-
sions if necessary.
2.3 | Outcome measures
The primary outcome measure was delivery occurring before 34 weeks 
of pregnancy. The secondary outcomes were delivery before 37 weeks 
of pregnancy, delivery before 32 weeks of pregnancy, delivery before 
28 weeks of pregnancy, delivery before 24 weeks of pregnancy, low 
delivery weight (<2500 g), need for mechanical ventilation, neonatal 
intensive care unit admission, 5- minute Apgar scores below seven, 
perinatal death, neonatal morbidity (respiratory distress syndrome, 
intraventricular or intracerebral bleeding, neonatal sepsis, or necrotiz-
ing enterocolitis), maternal adverse events, recurrent preterm labor, 
and discontinuation of treatment owing to adverse events.
2.4 | Assessment of risk of bias
Study quality and risk of bias were assessed using Cochrane 
Collaboration standards.11 This approach considers seven factors: (1) 
concealment of allocation; (2) random sequence generation; (3) suc-
cessive masking of participants and personnel to experimental and 
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control medications; (4) masking of outcome assessment; (5) incom-
plete outcome data description; (6) selective reporting of data; and 
(7) other bias. Bias assessments were made by two researchers (A.C.E. 
and E.O.) and were categorized as “low risk”, “high risk”, or “unclear 
risk” of bias; collaborative resolution was used for any disagreements.
2.5 | Data extraction
A standardized abstraction form was used to record data from the stud-
ies included. The randomization method, method for concealing alloca-
tion, individuals masked to treatment (providers, patients, and outcome 
assessors), participant data (trial location, demographic characteristics, 
inclusion and exclusion criteria, definition of recurrent SPTD, duration 
of pregnancy at randomization, cervical dilation, and effacement at trial 
entry), number of patients randomized, details of interventions (admin-
istration route, dose details, and treatment duration), and outcomes 
were coded by two researchers independently (A.C.E. and E.O.). Again, 
differences in coding were discussed until consensus was achieved.
2.6 | Statistical analysis
Cochrane Collaboration guidelines12 were followed when performing 
intent- to- treat analyses. Meta- analyses were only performed if study 
populations, interventions, and outcome measures were comparable. 
Summary relative risks (RRs) were calculated for dichotomous data. 
Mean differences were calculated for continuous data if a given out-
come was measured similarly across trials and standardized mean dif-
ferences were used if there was variation in the way an outcome was 
measured between studies.
Ultimately, no subgroup analyses were performed. A subgroup 
analysis to compare vaginal progesterone and intramuscular 17α- OHP 
with different types of vaginal progesterone was planned; however, it 
could not be performed owing to a lack of trials being identified that 
included these comparisons. Similarly, additional subgroup analyses of 
progesterone dose, duration of pregnancy at trial entry, and study set-
ting were abandoned owing to low cell sizes.
The heterogeneity of study data was measured using I2, which 
describes the percentage of total variation across studies that was 
due to heterogeneity and not chance.13 I2 values of at least 50% 
indicate substantial heterogeneity, values below 30% indicate low 
heterogeneity, and values of 30–50% indicate moderate heteroge-
neity.13 A fixed- effects model was considered appropriate for pooling 
studies when I2 was above 50%; a random- effects model was used for 
pooling other variables. The Egger test (with a cut- off value of <0.1) 
and visually assessed funnel- plot symmetry were used to assess publi-
cation bias.13 All analyses were performed with RevMan version 5.3.5 
(The Nordic Cochrane Centre, Copenhagen, Denmark) and P<0.05 
was considered statistically significant.
3  | RESULTS
There were three studies that met the inclusion criteria for the meta- 
analysis (Fig. 1) including a total of 680 patients with a history of 
preterm delivery (Table 1). Of these, 332 (48.8%) patients were ran-
domized to treatment with 17α- OHP and 348 (51.2%) to treatment 
with vaginal progesterone. The mean duration of pregnancy at ran-
domization was 16 weeks. Treatment continued until 36 weeks of 
pregnancy or delivery.
Delivery before 34 weeks of pregnancy was less frequent among 
patients treated with vaginal progesterone compared with those 
treated with 17α- OHP (19.3% vs 26.7%; RR 0.71, 95% confidence 
interval [CI] 0.53–0.95) (Fig. 2). Similarly, delivery before 32 weeks of 
pregnancy was also lower among patients treated with vaginal proges-
terone (12.4% vs 16.1%; RR 0.62, 95% CI 0.40–0.94) (Fig. 3). No dif-
ference was observed between the two treatment groups for delivery 
F IGURE  1 Study selection.
Records identified through 
database search (n=332)
Records identified through 
other sources (n=18)
Records screened 
(n=286)
Duplicate records (n=64)
Full-text articles 
screened (n=9)
Excluded (n=277)
Excluded (n=6)
• Not randomized 
trials (n=6)
Included in meta-
analysis (n=3)
TABLE  1 Demographic data of studies included in the meta- analysis.
Variable Bafghi et al.7 Elimian et al.8 Maher et al.9
Study setting Iran United States Saudi Arabia
Primary outcome measure Duration of pregnancy at delivery Spontaneous preterm delivery at 
<37 weeks of pregnancy
Spontaneous preterm delivery at 
<34 weeks of pregnancy
No. of patients included 33 145 502
Vaginal progesterone 16 79 253
Intramuscular progesterone 17 66 249
Intramuscular 17α- OHP dose 250 mg weekly 250 mg weekly 250 mg weekly
Vaginal progesterone dose and 
administration
200 mg daily, suppository 100 mg daily, suppository 90 mg daily, vaginal gel
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before 37 weeks or 28 weeks of pregnancy; however, non- significant 
trends favoring vaginal progesterone were observed for both out-
comes (Figs 4 and 5).
There were no differences between the rate of respiratory dis-
tress syndrome in the two groups (RR 1.02, 95% CI 0.65–1.60) 
(Fig. 6) or neonatal admission to the intensive care unit (RR 1.17, 
95% CI 0.49–2.79). A lower rate of adverse treatment reactions was 
observed among patients treated with 17α- OHP (12.3% vs 17.4%; 
RR 0.53, 95% CI 0.31–0.91); however, this finding was based on data 
from a single study. Owing to insufficient data, it was not possible 
to analyze the delivery rate before 24 weeks of pregnancy, recurrent 
preterm labor, low delivery weight, need for mechanical ventilation, 
5- minute Apgar score below seven, perinatal death, or neonatal mor-
bidity (including intraventricular or intracerebral bleeding, neonatal 
sepsis, and necrotizing enterocolitis).
4  | DISCUSSION
In the present meta- analysis, patients who were treated with vagi-
nal progesterone demonstrated significantly lower rates of SPTD 
before 34 weeks of pregnancy and before 32 weeks of pregnancy 
F IGURE  2 Spontaneous preterm delivery at <34 weeks of pregnancy.
F IGURE  3 Spontaneous preterm delivery at <32 weeks of pregnancy.
F IGURE  4 Spontaneous preterm delivery at <37 weeks of pregnancy.
F IGURE  5 Spontaneous preterm delivery at <28 weeks of pregnancy.
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compared with patients treated with 17α- OHP. To the best of our 
knowledge, the present meta- analysis was the first to compare out-
comes from randomized controlled trials assessing the efficacy of 
prophylactic vaginal progesterone and intramuscular progesterone in 
patients with singleton pregnancies and a history of SPTD, regard-
less of cervical length. Contrary to a subset of currently available 
guidelines for progesterone administration, the present study found 
that vaginal and intramuscular formulations were at least compara-
ble in their efficacy preventing recurrent SPTD and preventing some 
associated forms of neonatal morbidity. In fact, vaginal progesterone 
could even be superior to intramuscular 17α- OHP in decreasing the 
risk of delivery prior to 34 weeks of pregnancy. Similarly, the vaginal 
formulation could have a more favorable risk profile, based on the 
outcomes measured.
There were several limitations in the present study. First, each trial 
used different formulations of vaginal progesterone. Unfortunately, 
the safest and most effective dose of vaginal progesterone for SPTD 
prophylaxis has not been established. This variation limits the validity 
of the results. Second, the individual studies were limited by the low 
participant numbers and secondary outcome heterogeneity. However, 
a strength of all three studies included was the stringent randomiza-
tion, without significant demographic differences between the treat-
ment groups.
As there were only three studies in the meta- analysis, many sec-
ondary outcomes could not be assessed. Notably, these included peri-
natal death and the need for mechanical ventilation, complicating the 
assessment of the neonatal mortality and severe morbidity of vaginal 
and intramuscular progesterone treatment.
Ultimately, the present meta- analysis, despite some unavoidable 
flaws, has shed light on a possible alternative to intramuscular proges-
terone, the current gold- standard treatment for patients with a history 
of preterm delivery. Further randomized controlled trials are certainly 
warranted to explore this question further.
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F IGURE  6 Respiratory distress syndrome.
Study or Subgroup
Bafghi 2015
Elimian 2016
Maher 2012
Total (95% CI)
Total events
Heterogeneity: Chi²=5.21, df=2 (P=0.07); I²=62%
Test for overall effect: Z=0.08 (P=0.93)
Events
7
9
19
35
Total
16
79
253
348
Events
2
5
26
33
Total
17
66
249
332
Weight
5.8%
16.2%
78.0%
100.0%
M-H, Fixed, 95% CI
3.72 [0.90, 15.31]
1.50 [0.53, 4.27]
0.72 [0.41, 1.27]
1.02 [0.65, 1.60]
Vaginal progesterone 17 OHPC Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours vag progesterone Favours 17 OHPC
